Compare · ELV vs MDXH
ELV vs MDXH
Side-by-side comparison of Elevance Health Inc. (ELV) and MDxHealth SA (MDXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and MDXH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $82.89B, about 3872.9x MDXH ($21.4M).
- Over the past year, ELV is up 38.4% and MDXH is down 83.0% - ELV leads by 121.4 points.
- ELV has been more active in the news (6 items in the past 4 weeks vs 4 for MDXH).
- ELV has more recent analyst coverage (23 ratings vs 5 for MDXH).
- Company
- Elevance Health Inc.
- MDxHealth SA
- Price
- $382.33+2.52%
- $0.42-1.51%
- Market cap
- $82.89B
- $21.4M
- 1M return
- -2.28%
- -25.48%
- 1Y return
- +38.38%
- -83.03%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 4
- Recent ratings
- 23
- 5
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Latest ELV
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.
Latest MDXH
- Amendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SA
- SEC Form 6-K filed by MDxHealth SA
- Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
- SEC Form 4 filed by Officer Sollee Joseph
- SEC Form 4 filed by Director Hardison Don M
- SEC Form 4 filed by Chief Executive Officer Mcgarrity Michael
- SEC Form 4 filed by VP, Finance and Accounting Oconnell Brendan
- SEC Form 4 filed by Director Hoffman Koen
- SEC Form 4 filed by Chief Commercial Officer Bellano John